)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Arbutus Biopharma (ABUS) investor relations material
Arbutus Biopharma Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary6 Aug, 2025
Executive summary
Achieved net income of $2.5 million for Q2 2025, reversing a $19.8 million loss in Q2 2024, driven by $9.6 million deferred revenue after terminating the Qilu partnership and regaining global rights to imdusiran.
Streamlined operations with a 57% workforce reduction, exit from headquarters, and discontinuation of in-house research, incurring a $12.4 million restructuring charge in Q1 2025.
Expanded Scientific Advisory Board and made board changes, including the appointment of Dr. Roger Sawhney and Dr. Harry Janssen, and resignation of Anuj Hasija.
Ongoing patent litigation against Moderna and Pfizer/BioNTech for LNP technology, with summary judgment and trial dates set for 2025-2026 and five international lawsuits filed in March 2025.
Focused on advancing clinical development of imdusiran (AB-729) and AB-101 for chronic hepatitis B, with positive Phase 2a data and ongoing Phase 1a/1b trial.
Financial highlights
Q2 2025 revenue rose to $10.7 million from $1.7 million in Q2 2024, mainly due to $9.6 million deferred revenue recognition from Qilu partnership termination.
Operating expenses dropped to $9.3 million in Q2 2025 from $23.3 million in Q2 2024, reflecting lower R&D and G&A costs.
Cash, cash equivalents, and marketable securities totaled $98.1 million as of June 30, 2025, with no outstanding debt.
Cash used in operations for the first half of 2025 was $29.1 million, down from $33.8 million in the prior year period.
Net income per share was $0.01 (basic and diluted) for Q2 2025, compared to a loss of $0.11 per share in Q2 2024.
Outlook and guidance
Sufficient cash resources to fund operations for at least the next 12 months.
Net cash burn expected to significantly decrease in 2025 due to restructuring and cost management.
Additional funding may be required for future pipeline development, patent litigation, and potential milestone payments.
Remaining restructuring payments expected in the second half of 2025.
Ongoing support for patent litigation against Moderna and Pfizer/BioNTech, with key trial dates in 2026.
Key LNP litigation milestones for 2025-2026?
Cash runway given current operating burn?
Leveraging imdusiran global rights for value?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Arbutus Biopharma earnings date
Q3 20256 Nov, 2025
Next Arbutus Biopharma earnings date
Q3 20256 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Arbutus Biopharma Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of therapies for viral diseases. The company utilizes its expertise in RNA interference (RNAi) technology and small molecule development to address diseases such as chronic hepatitis B. Arbutus conducts research and development to advance its proprietary drug candidates and explore combination treatment approaches. The company is headquartered in Warminster, Pennsylvania, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage